Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $36.33 Conse

Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) have earned an average recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have issued ratings on the […]

Related Keywords

Arthura Levin , , Vanguard Group Inc , Needham Company , Nasdaq , Securities Exchange Commission , Avidity Biosciences Company Profile , Avidity Biosciences Inc , Mirae Asset Global Investments Co , Cantor Fitzgerald , Wells Fargo Company , Raymond James Financial Services Advisors Inc , Avidity Biosciences , Get Free Report , Chardan Capital , Director Arthur , Exchange Commission , Capital Partners , Asset Global Investments , Raymond James Financial Services Advisors , James Financial Services Advisors , Get Free , Avidity Biosciences Daily , Nasdaq Rna , Rna , Medical , Ratings , Consensus ,